Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stacy Smith

Dermatology Encinitas, CA Medical Doctor

NPI 1780651760 CMS profile 172031

561 Saxony Pl, Suite 102, Encinitas, CA 92024

Open in the dashboard

General payments

$993,478

692 records reported · program years 2019–2025

Research payments

$325,454

Paid to them · 54 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,905,098 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Stacy Smith of Encinitas, CA is reported in the CMS Open Payments database as having received $993,478 across 692 general payments and $325,454 in research payments paid to them. Separately, studies naming them as principal investigator received $6,905,098 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $90,862 38
2024 General $108,764 65
2024 Research $20,888 6
2023 General $167,570 125
2023 Research $67,949 9
2022 General $205,321 167
2022 Research $99,392 10
2021 General $75,438 46
2021 Research $7,507 4
2020 General $106,980 62
2020 Research $30,023 10
2019 General $238,543 189
2019 Research $99,695 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Smith
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Stacy Smith were reported at $90,862. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Stacy Smith Dermatology median Middle half National median
2019 $238,543 $454 $129–$1,240 $163
2020 $106,980 $235 $81–$756 $114
2021 $75,438 $377 $108–$1,108 $132
2022 $205,321 $514 $143–$1,391 $149
2023 $167,570 $607 $159–$1,674 $160
2024 $108,764 $751 $204–$1,903 $164
2025 $90,862 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $451,742 344 payments
  2. AbbVie, Inc. $303,321 209 payments
  3. Janssen Scientific Affairs, LLC $122,329 70 payments
  4. Janssen Biotech, Inc. $59,315 42 payments
  5. Krystal Biotech Inc $21,775 2 payments
  6. Dermira, Inc. $19,661 13 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $5,588 3 payments
  8. UCB, Inc. $3,540 1 payment
  9. Incyte Corporation $3,334 2 payments
  10. LEO Pharma Inc. $2,740 1 payment
  11. Other $132 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $808,212 322 payments
  2. Consulting Fee $100,449 28 payments
  3. Travel and Lodging $61,683 166 payments
  4. Honoraria $13,750 4 payments
  5. Food and Beverage $9,232 163 payments
  6. Education $153 9 payments
Products named General payments · program years 2019–2025
  1. TALTZ $187,465 152 payments
  2. TREMFYA $180,267 110 payments
  3. SKYRIZI $144,224 86 payments
  4. OLUMIANT $136,707 82 payments
  5. RINVOQ $119,779 101 payments
  6. EBGLYSS $75,718 36 payments
  7. HUMIRA $25,072 18 payments
  8. QBREXZA $19,661 13 payments
  9. STELARA $5,807 6 payments
  10. SIMPONI ARIA $4,457 5 payments
  11. Other $4,039 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Almirall LLC $133,141 11 payments
  2. Eli Lilly and Company $98,667 22 payments
  3. Nielsen BioSciences, Inc. $59,635 3 payments
  4. Arcutis Biotherapeutics, Inc. $16,790 6 payments
  5. Pfizer Inc. $13,340 6 payments
  6. Dermira, Inc. $3,193 5 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $688 1 payment

Records

746 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record